Product Images Sacubitril And Valsartan Sacubitril And Valsartan
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 11 images provide visual information about the product associated with Sacubitril And Valsartan Sacubitril And Valsartan NDC 43598-645 by Dr. Reddy's Laboratories Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
container1 - container1
container2 - container2
container3 - container3
figure1 - figure1
figure2 - figure2
Population Description: The text provides information on the geometric mean ratio and 90% CI for various factors including AUC Crnax, renal impairment levels (mild, moderate, severe), hepatic impairment levels (mild, moderate), age groups (≥65 years, 18-45 years), gender (male/female), ethnicity (Asian - Japanese and Chinese/Caucasian, Black/Caucasian), and changes relative to reference values. This data can be valuable for understanding the impact of these factors on specific outcomes.*
figure3 - figure3
The text describes a comparison study called PARADIGM-HF, where patients were treated with either Enalapril or Sacubitril and Valsartan. The study evaluated the time to first occurrence of cardiovascular death or heart failure hospitalizations, time to occurrence of cardiovascular death, and time to occurrence of heart failure hospitalizations. The results of the study show significant differences between the two treatments, with p<0.0001 indicating a strong statistical significance favoring Sacubitril and Valsartan over Enalapril in reducing cardiovascular events.*
figure4 - figure4
The text provides data on various subgroups of the population based on age, gender, weight, race, region, medical conditions like diabetes and hypertension, prior medication usage, time since diagnosis of heart failure, cause of heart failure, and treatment with medications like Sacubitril and Valsartan and Enalapril. It also includes information on hazard ratios comparing the effectiveness of Sacubitril and Valsartan versus Enalapril. This data can be used for analysis and evaluation in the context of heart failure treatment.*
figure5 - figure5
figure6 - figure6
figure7 - figure7
This text provides information on hazard ratios for different treatments (Sacubitril and Valsartan vs. enalapril, and Sacubitril and Valsartan vs. valsartan) in clinical trials such as PARADIGM-HF and PARAGON-HF. It also includes data on left ventricular ejection fraction at screening in percentage. The text shows numeric values and headings for these parameters, which could be used for further analysis or comparisons in a medical context.*
structure - structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
